|Bid||14.36 x 800|
|Ask||14.83 x 1400|
|Day's Range||13.02 - 15.04|
|52 Week Range||10.42 - 27.85|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.60|
Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) were sinking 28% as of 11:32 a.m. EDT on Tuesday. This big decline came after the company reported positive results from a phase 1 study evaluating SNDX-5613 in treating leukemia. The company reported a 48% overall response rate in patients with mixed lineage leukemia-rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias.
The results of Syndax's Phase 1 trial of a blood-cancer-treatment candidate came up short of an investment firm's estimate.
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company's highly selective, oral menin inhibitor. Information on how to access the live video webcast and accompanying slide presentation can be found below.